Overview

• Samsung Biologics has unveiled plans to spin off its biosimilar development business into a new entity, Samsung Epis Holdings, which will oversee Samsung Bioepis as a wholly owned subsidiary.
• The move addresses client concerns about potential conflicts of interest between its CDMO and biosimilar operations, enhancing operational independence for both units.
• Shareholders will receive approximately 0.65 shares in Samsung Biologics and 0.35 shares in Samsung Epis Holdings for each share held, enabling distinct market valuations.
• Key milestones include the submission of a securities report on July 29, a shareholder meeting on September 16 for approval, and the effective spin-off on October 1, with both entities relisting on October 29.
• Samsung Biologics plans to focus on expanding its CDMO business globally, while Samsung Epis Holdings will concentrate on broadening its biosimilar portfolio and exploring emerging technologies.